BU combined with CY, the preferred preparatory regimen for thalassemic patients, is associated with a substantial incidence of graft rejection especially in patients with advanced disease stage. This study retrospectively analyzes the outcome of 75 consecutive pediatric patients with b-thalassemia who underwent HLA-matched sibling transplantation after anti-thymocyte globulin (ATG)-containing myeloablative conditioning regimens. With a median follow-up of 9 years (range 1--15 years), the overall survival (OS) and thalassemia free survival (TFS) rates were 96% and 92%, respectively. Both the estimated TRM and the cumulative incidence of rejection/failure were 4%. The cumulative incidences of acute GVHD grade II --III and grade III were 20% and 5.3%, respectively. No patient developed acute GVHD grade IV. Only two patients developed extensive chronic GVHD. The estimated OS and TFS for patients with Class 1 and 2 disease according to Pesaro criteria were 96.3% and 94.4%, whereas for patients with Class 3 disease they were 94.1% and 88.2%, respectively. In our series, the use of myeloablative conditioning regimens, which include ATG for the transplantation of thalassemic children from matched sibling donors, resulted in excellent outcomes with very low incidences of TRM and rejection. 
INTRODUCTION
Despite considerable progress in the management of thalassemia major over the last three decades resulting in significant improvement in survival, hematopoietic SCT remains the only curative approach for children with b-thalassemia major to date. 1, 2 In the presence of an HLA-matched related donor, hematopoietic SCT should be performed as early as possible as the outcome is better in younger patients. 3 Since the first successful transplantation for thalassemia, approximately 30 years ago, hematopoietic SCT efficacy and safety have improved substantially; recent data from the most experienced group in Pesaro reported probabilities of overall survival (OS) and thalassemia free survival (TFS) of 90% and 85%, respectively for pediatric patients after hematopoietic SCT from a matched sibling donor. 4 In more detail, the probabilities of OS, TFS, rejection and non-rejection mortality for children o17 years-old without advanced disease (class 1 and 2 according to Pesaro classification) were 97%, 89%, 8% and 3%, respectively, whereas for children with advanced disease (class 3) they were 87%, 80%, 12% and 10%, respectively. 5 Conditioning regimen consisted of BU/CY for children with risk class 1 and 2 disease, 44 years of age, whereas thiotepa was added in younger children. Children with advanced disease were pretreated with hydroxyurea, azathioprine and fludarabine with the aim to reduce rejection/ failure rates. 6 Myeloablative conditioning regimens containing ATG have been applied in the setting of hematopoietic SCT from alternative donors, such as unrelated volunteer donors, phenotypically matched or mismatched related donors and in second transplants using matched siblings. 7 --9 Although the addition of ATG for matched sibling hematopoietic SCT for thalassemia seemed to improve the results in several centers outside Italy, its role in this setting remains controversial. 10 --12 The transplantation program for thalassemia in our institution began in 1994, when rejection/failure rates according to Pesaro data from 220 transplanted patients varied between 12 and 30%. 13 The occurrence of three graft failures in the first six patients conditioned with BU 16 mg/kg and CY 200 mg/kg led us to add ATG to the myeloablative regimen on an institution-protocol basis. We report the results of hematopoietic SCT from matched sibling donors in 75 consecutive thalassemic patients o18 years old transplanted in our center incorporating ATG as part of the myeloablative preparative regimen.
PATIENTS AND METHODS Patients
From November 1995 until December 2009, 75 consecutive patients affected by transfusion-dependent b-thalassemia underwent hematopoietic SCT from matched related donors in our institution. Written informed consent was obtained from the parents and from both patients and donors if 412 years. Data were collected and analyzed in December 2010 retrospectively after approval by the Human Investigational Review Board of Aghia Sophia Children's Hospital. All but four patients were classified into three categories on the basis of inadequate chelation, hepatomegaly and the presence of portal fibrosis in the liver.
14 Pesaro Class 1 patients had none of these adverse risk factors, class 2 patients had one or two and class 3 had all three. Risk class was not determined in four patients because liver biopsy was not performed. However, all of these four patients had hepatomegaly and irregular iron chelation and, therefore, could be classified at least as class 2. Out of the 71 patients, 16 were assigned to risk class 1, 38 to class 2 and 17 to class 3. Patients transplant characteristics and outcome are shown in Table 1 .
Transplantation procedure
Fifty-five patients were conditioned with oral BU 14 --16 mg/kg plus CY 150 --200 mg/kg and rabbit ATG (thymoglobulin, 2.5 mg/kg/day from day À5 to À1). Patients with advanced disease (class 3) received BU 14 mg/kg combined with CY 150 mg/kg. The remaining 20 patients, treated after September 2005 received Busilvex i.v. combined either with CY 200 mg/kg and ATG 12.5 mg/kg (14 patients), or with CY 150 mg/kg, ATG 12.5 mg/kg and fludarabine 100 mg/m 2 total dose from day À7 to À4 (six patients Pesaro class 3). ATG was given at a continuous rate over 6 h following premedication with Dimetinden and 2 mg/kg prednisolone immediately before the start of the drug. Stem cell source was BM in 68 cases, PBSCs in two cases and combined BM and cord blood from the same sibling donor in five cases.
GVHD prophylaxis
GVHD prophylaxis consisted of CsA at a dose of 3 --6 mg/kg per day i.v. starting from day À1, switched to oral formulation as soon as oral feeding was permitted and short course MTX (15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3 and þ 6). CsA dosing was adjusted according to the monitoring of blood levels. CsA was administered for 9 months, and in the absence of clinical or laboratory signs of GVHD it was gradually tapered over the following 3 months.
Infection prophylaxis and supportive care
All patients were treated in positive-pressured and air HEPA filtered isolation rooms and fed with a low-bacteria diet. Supportive care included antibacterial prophylaxis with ciprofloxacin starting on day À4, which was replaced by penicillin as soon as the ANC exceeded 1000/mL and continued until the revaccination program was completed. Pneumocystis jiroveci (carinii) prophylaxis consisted of trimethoprime/sulfamethoxazole starting on day À10 until day À1, and after engraftment with pentamidine IV until platelets exceeded 50000/mL, and then with trimethoprime/sulfamethoxazole until day þ 180. Fluconazole as antifungal prophylaxis was given from day À4 and stopped as soon as neutrophils exceeded 1000/mL. Acyclovir was administered from the start of conditioning until day þ 180 for HSV and VZV prophylaxis. CMV reactivation was monitored either by expression of the pp65 Ag or by quantitative PCR on a weekly basis until day þ 100. According to an established on-site protocol, the detection of virus before engraftment led to preemptive treatment with i.v. foscarnet or else with ganciclovir with a minimum of 2 weeks of induction therapy. Blood cultures were performed to identify the etiology of bacterial and fungal infections. Specimens were submitted for microbial and fungal cultures according to standard methods. Antibiotic therapy was started when patients became febrile, and antifungal therapy was added in the presence of either clinical evidence of fungal infection or fever persisting after 5 days of antibiotic therapy. All blood products administered after transplantation were irradiated with 30 Gy. After the completion of 12 months, all patients who did not have evidence of GVHD and were off all immunosuppressive drugs, were vaccinated against polio, diphtheria, tetanus, hemophilus influenza and pneumococcus (live vaccines were not used).
Clinical outcomes and definitions
Incidence and severity of GVHD was defined as per established criteria. 15 Time to neutrophil engraftment was defined as the first of three consecutive days with ANC above 500/mL. Time to platelet engraftment was defined as the first of three consecutive days with a platelet count above 20 000/mL (without platelet transfusion support). Primary graft failure was defined by persistent pancytopenia with no evidence of hematological recovery of donor cells beyond 30 days after transplant whereas secondary graft failure or rejection was defined as a rapid decrease in neutrophil count after successful engraftment followed by thalassemia recurrence. Graft rejection was further defined as early (graft rejection within 60 days of initial engraftment) or late (graft rejection occurring 60 days after SCT and initial engraftment). OS was defined as the time from transplant to death from any cause. TFS was defined as the time from transplant to recurrence of transfusion dependence or death from any cause. CMV infection was defined as a positive PCR assay or a CMV copy number X100 copies/mL. CMV disease was defined as the demonstration of CMV in biopsy of visceral sites (by culture or histology). All fungal infections were documented as probable, possible and proven fungal infections based upon previously published criteria. 16 Chimerism monitoring. Chimerism was routinely monitored at 30, 60, 100, 120 and 365 days following SCT. In cases with mixed chimerism, monitoring was performed in shorter intervals and as clinically indicated. The percentage of donor/recipient DNA was evaluated using PCR-based analysis of selected polymorphic STRs loci. Chimerism was assessed on BM, peripheral blood and on burst forming unit-erythroid (BFU-E) colonies.
Statistical analysis
OS and thalassemia-free-survival were estimated according to the KaplanMeier method. Probabilities of rejection, GVHD and infections were calculated by using the cumulative incidence estimator. The impact of the following parameters on OS and TFS was examined: (1) age of the recipient (above vs below the median value) (2) serum ferritin (above vs, the median value) (3) Pesaro class, (4) total nucleated cells per kg (contained in the graft) (above vs below the median), (5) CD34 þ cells per kg contained in the graft (above vs below the median) and (6) BU (oral vs i.v. BU). Both univariate and multivariate analysis of prognostic factors were made according to the log-rank test and to a stepwise Cox proportional hazards regression model, respectively. Death due to any reason was considered as a competing event when estimating the cumulative incidence of GVHD, rejection/failure and infectious complications. NCSS-software (NCSS, Kaysville, UT, USA) was used for the estimation of cumulative incidence rates in the presence of competing risk.
RESULTS

Engraftment
All patients achieved initial donor cell engraftment. Neutrophil and platelet engraftment are shown in more detail in Table 1 . Three patients experienced secondary graft failure at 3, 5 and 6 months after transplant, respectively. The first child was a 18-month-old female with class 1 disease, the second was a 15-yearsold male with class 3 disease, while the third patient was a 11-year-old female with unknown disease risk class (liver biopsy was not performed, but she was considered at least as class 2 because of the presence of hepatomegaly and history of inadequate chelation). Graft failure was manifested by gradual loss of donor cells and recovery of autologous haematopoiesis in all three patients. The first two patients are alive and transfusion dependent, whereas the third underwent a successful second hematopoietic SCT using the same donor, and is currently alive and transfusion-free three years after the second transplant. The cumulative incidence of graft failure for the whole cohort of our patients was 4% (95% confidence interval (CI), 1.3 --12.1%; Figure 1 ). We did not observe any statistically significant difference in graft failure rates between patients classified to class 1 and 2 (n ¼ 54) in comparison with those classified to class 3 (n ¼ 17). The cumulative incidences of rejection rates were 3.8% and 5.3% for class 1, 2 and 3, respectively. None of the factors mentioned in Methods had any statistically significant influence on rejection rates.
GVHD
The cumulative incidences of grade II --III and III acute GVHD were 20% (95% CI, 12.7 --31.5%) and 5.3% (2 --13.8%). None of our patients experienced grade IV acute GVHD. All patients with a cute GVHD had an excellent response to first line treatment with steroids. In all, 8 of 75 patients developed chronic GVHD accounting for a cumulative incidence of 10.6% (95% CI, 5.5 --20.5%). Among them only two developed an extensive chronic GVHD. Chronic GVHD resolved or improved in all affected patients, and currently none of these patients are under immunosuppressive therapy.
Overall survival and thalassemia free survival With a median follow-up of 9 years (range 1 --15) OS rate was 96% (Figure 2 ). Three patients 47 years at the time of transplantation died at 20 days, 6 months and 4 months after transplantation, owing to cerebral hemorrhage following refractory thrombocytopenia, disseminated toxoplasmosis and pneumonia because of pneumocystis jiroveci (carinii), respectively. The Kaplan-Meier estimate of TRM rate was 4% (Figure 2 ). In all, 69 out of 75 patients are alive and free of thalassemia with Lansky/Karnofsky score of 100%. A total of 67 out of these 69 patients are in a state of complete donor chimerism, whereas two of them remain mixed chimeras. The Kaplan-Meier analysis estimated that thalassemia-free survival was 92% (Figure 2) . None of the factors mentioned under Patients and methods had any statistically significant influence on OS or TFS. The estimated OS and TFS for patients with low risk (Class 1 and 2) disease according to Pesaro criteria they were 96.3% and 94.4%, whereas for patients with high risk (Class 3) disease they were 94.1% and 88.2%, respectively (Figures 3 and 4) . In more detail the probabilities of OS and TFS for class 1, 2 and 3 patients were 100%, 97.2%, 94.1%, and 94.1%, 97.2% and 88.2%, respectively, while the cumulative incidence of graft rejection was 5.8%, 0% and 5.8%, respectively. 
Infectious complications
In our study, 20 patients (29%; 95% CI 15 --40%) developed at least one episode of CMV reactivation during the first 6 months after transplantation ( Figure 5 ). The median time to onset of the first CMV-reactivation episode was 40 days (range, 9 --96). A total of 8 out of 20 patients had a second episode of CMV-reactivation at a median time of 55 (range, 20 --130 days). Only three patients had repeated episodes of CMV-reactivation. Episodes of CMV-reactivation were treated successfully and no patient developed CMV disease. Five patients experienced localized herpes zoster (HZ) and were treated with acyclovir for 7 to 14 days. Median time of HZ occurrence was 12 months (range, 8 --18 days) after transplant. At the time of HZ, no patient was on acyclovir prophylaxis. Among our 75 patients, only 2 developed grade III and 7 developed grade II hemorrhagic cystitis. During the first 6 months after transplantation, 11 episodes of bacteremia occurred in 10 patients (13.3%; 95% CI, 7.5 --23.7%). The median time to onset of the bacteremia was 35 (range, 1 --124) days ( Figure 5 ). In three patients bacteremia occurred during the neutropenic phase, at days 1 and 8, and in three after hematopoietic SCT. Among 11 episodes of bacteremia, 7 were due to Gram-positive, whereas the remaining 4 were due to Gram-negative bacteria. Two more episodes of bacteremia due to Gram-negative bacteria occurred in a patient with chronic GVHD during the second year after transplantation.
No patient developed probable or definite invasive fungal infections. However, among the three deaths in our series, two were directly attributed to infections. Both infections occurred in the absence of GVHD at 6 and 4 months post transplant, because of disseminated toxoplasmosis and pneumocystis jiroveci (carinii) pneumonia, respectively.
Other complications During treatment with ATG, side effects were common. The observed clinical symptoms included chills, fever, hypotension, Coombs positive hemolytic anemia, edemas, thrombocytopenia and skin rashes. Side effects were most severe on day 1, and completely resolved within a few days in all patients after treatment with high-dose steroids and antihistamines.
Four patients developed veno-occlusive liver disease of mild-tomoderate severity that was successfully treated with fluid restriction and diuretics. Grade II---III late-onset hemorrhagic cystitis (beyond 1 week after transplant) occurred in nine patients and was successfully treated with hyperhydration, forced diuresis and bladder irrigation. Three additional patients experienced seizures attributable to oral BU, CY and encephalitis of unknown origin, respectively.
Chimerism
During the first year after transplantation, 25 of 72 surviving patients developed mixed chimerism (410% residual host cells) resulting in graft rejection and reconstitution of thalassemic hematopoiesis only in three cases. Only 2 of the remaining 22 patients have mixed chimerism after the first year with 30% and 40% donor cells, respectively, without, however, any transfusion requirements.
DISCUSSION
Initial reports on pediatric patients with b-thalassemia undergoing hematopoietic SCT from matched sibling donors showed that the outcome was significantly hampered because of non-rejection mortality and increased failure/rejection rates. Non-rejection mortality has been mainly observed in high risk patients (class 3 according to Pesaro criteria) whereas rejection or engraftment failure appeared to occur in both low-and high-risk patients. 17, 18 Subsequently, the most commonly used conditioning regimen BU 14 mg/kg and CY 200 mg/kg was modified by reducing CY to 160 mg/kg in class 3 patients in an attempt to decrease TRM. Although TRM could be significantly reduced, this was achieved at the expense of an increased rejection rate from 12 to 30%, thus overall TFS was not affected by the dose modification. 18 A different approach was introduced in 1997 by the Pesaro group for the conditioning of high risk thalassemic patients for transplantation. It was based on preconditioning chemotherapy (azathioprine and hydroxyurea) starting on day À45 and fludarabine from day À17 through day À13 to ablate the expanded thalassemic marrow and increase immunosuppression followed by BU 14 mg/kg per CY 160 mg/kg. This approach has substantially improved the outcome of matched sibling hematopoietic SCT in high risk (Class 3) children offering TFS of 85%. 6 This protocol still remains the conditioning regimen of choice for patients with advanced disease. Regarding low risk patients (Class 1 and 2), the only change in the last 7 years is the addition of thiotepa to the BU/CY schema for children o4 years who also have an increased rejection rate when conditioned with a BU/CYbased regimen alone. 5 There are no randomized trials comparing preparative regimens with vs without ATG in thalassemia; however, several centers outside Italy incorporated ATG in conditioning regimens with the intention to reduce rejection rates. Li et al. from Hong Kong reported a 5-year OS and TFS as well as a rejection rate of 86%, 82% and 5%, respectively in 44 patients conditioned with BU/CY and ATG. 19 Similarly, Lawson et al. from UK reported an 81% overall TFS and 13.2% probability for rejection in an analysis of 55 consecutive BM transplants. However, with the addition of anti-lymphocyte globulin (ALG) or gampath and or fludarabine in the conditioning regimen, only 2 out of 43 patients (4.6%) have experienced rejection. 12 An alternative approach used in thalassemic patients is the complete substitution of CY by fludarabine and ATG in a BU-based preparative regimen of reduced intensity. Although the first results from three small cohorts of patients seemed promising with an overall survival of 100% and TFS about 80%, larger cohorts of patients are required to confirm the benefits of a reduced intensity conditioning for thalassemia. 20 --22 In a recent study, Bernardo et al. 23 showed that the use of treosulfan-based regimens in 20 thalassemic patients resulted in a probability of OS and TFS of 95% and 85%, respectively, concluding that randomized trials comparing treosulfan-based vs BU-based regimens are warranted.
Because of a high rate of graft failure (50%) in our first six patients transplanted with BU/CY, 24 we added ATG to the BU/CY or to BU/fludarabine (Flu)/CY for class 3 patients since 2005, and used i.v. BU instead of oral in all patients over the last 5 years. With 96% OS and 92% TFS at a median follow-up time of 9 years, our results are at least equivalent to recent data from Lucarelli's group in Rome reporting 3-year OS and disease-free survival of 91% and 87% respectively, in 68 patients transplanted between June 2006 and March 2009. 25 We cannot make a direct comparison of ATGcontaining regimens vs non-ATG because the number of our patients who did not receive ATG is very small. However, in our hands, the results without ATG in the conditioning seemed very discouraging in terms of rejection rates, and led us to the regimen modification.
Additionally, in other published series 20, 21, 23 with regimens containing ATG but omitting or substituting a CY or BU seem to have inferior results compared with our series, and we believe that our data favor the use of BU/CY/ATG regimen.
We could not find any difference, neither between different Pesaro class risk patients nor between patients conditioned with oral vs i.v. BU. It is not unreasonable to assume that the abolition of differences between risk classes could be attributed to the use of ATG. The successful application of ATG in reducing graft rejection has also been very well documented in patients with severe aplastic anemia and sickle cell disease. 26, 27 Furthermore, peritransplant administration of ATG has been shown to be effective in reducing GVHD incidence and TRM in various transplant settings from unrelated donors. 28, 29 Zakerinia et al. 30 reported a significant reduction in the incidence of grade IV acute and chronic GVHD by adding ATG to the conditioning regimen for thalassemia. We also observed low incidences of both acute and chronic GVHD of 20% and 10%, respectively. None of the children developed grade IV acute GVHD, and both children who developed extensive chronic GVHD responded to steroid treatment and are currently alive, without immunosuppressive therapy. Recent data from Italy reported acute GVHD (Grade 2 --4) rates of 35% with the TRM at 3 years to be significantly higher in patients with acute GVHD (23%) compared with patients with grade 0 --1 acute GVHD (5%, P ¼ 0.013). 31 No death was attributed or related to acute or chronic GVHD in our cohort. It is therefore reasonable to assume that the inclusion of ATG in our regimens contributed substantially to the favorable outcome in our patients by minimizing graft rejection on the one hand and by reducing GVHD on the other.
In a more recent clinical report, Sabloff et al. analyzed the data on 179 pediatric patients with b-thalassemia, who received HLAidentical sibling BM transplants between 1995 and 2001, reported to the International Bone Marrow Transplant Registry from 12 countries other than Italy. 32 The 5-year survival probability of 91% for patients Pesaro class 2 in this series could be considered comparable with that observed in Pesaro, but the outcome of high risk patients with 64% overall survival for class 3 patients is clearly inferior to previously published data from Pesaro. The use of ATG in 43% of the cases had no apparent association with the risk of GVHD, nor with rejection in this analysis. However, the heterogeneity of this patient population in terms of ethnicity, criteria for assignment to risk categories, conditioning regimens and supportive care might not allow this multicenter registry-based study to show a possible favorable effect of ATG as it could be shown in a single center study.
Both myeloablative and non-ablative conditioning regimens containing ATG have been associated with increased infection risk. 33, 34 In the present study, the incidence of CMV reactivation and bacterial infections was 29% and 13%, respectively, whereas no invasive fungal infections have been detected as probable or definitive. Neither EBV-related post transplant lymphoproliferative disease nor second malignancies were observed. We cannot confirm recent results reporting increased incidence (58%) of lateonset hemorrhagic cystitis (grade II --IV) that is usually related to an infectious cause in patients with thalassemia or sickle cell disease who received ATG in the conditioning regimen. 35 According to the Pesaro group, the use of ATG in the conditioning of thalassemic patients is recommended only for non-genotypically HLA identical related donors or in the setting of a second transplant. However, several centers have recently supported adding ATG in the first transplantation conditioning regimen of class 3 patients from identical sibling donors. 22, 23, 36 Our results suggest that an ATG-containing myeloablative conditioning regimen followed by hematopoietic SCT from HLA-matched related donor might be a reasonable approach not only for high risk patients but also for risk class 1 and 2 thalassemic children with a matched sibling donor.
Both TRM and relapse/failure rate was 4% for the entire cohort. These rates suggest that, even in view of the significant improvements in supportive therapy resulting in long life expectancy, transplantation should be offered to all children with thalassemia, independent of class risk, if a matched sibling is available.
